Goldfinch Bio, Takeda sign deal for CB1 monoclonal antibody to treat rare and metabolic kidney diseases

Image: Takeda Midosuji Building, headquarters of Takeda Pharmaceutical Company, in Chuo-ku, Osaka, Japan. Photo: courtesy of J o / Wikimedia Commons.